Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
89.53
+1.04 (+1.18%)
Other Pre-Announcement

Merck Reports Second-Quarter 2022 Worldwide Sales Of $14.6 Billion, Up 28%

Published: 07/28/2022 10:47 GMT
Merck & Co Inc (MRK) - Merck - Second-quarter 2022 Worldwide Sales Were $14.6 Billion, an Increase of 28%.
Merck - Qtrly Keytruda Sales Grew 26% to $5.3 Billion; Excluding Impact From Foreign Exchange, Sales Grew 30%.
Merck - Qtrly Gardasil/gardasil 9 Sales Grew 36% to $1.7 Billion; Excluding Impact From Foreign Exchange, Sales Grew 40%.
Merck - Q2 2022 GAAP EPS From Continuing Operations Was $1.55; Q2 2022 Non-GAAP EPS Was $1.87.
Merck - Qtrly Januvia / Janumet Sales of $1.23 Billion, Down 2%.
Merck - Co Raises & Narrows Expected FY 2022 Worldwide Sales Range to Be Between $57.5 Billion and $58.5 Billion.
Merck - Co Narrows Expected FY 2022 Non-GAAP EPS Range to Be Between $7.25 and $7.35, Including Negative Impact From Foreign Exchange of About 3%.
Merck - Co Expects FY 2022 GAAP EPS to Be Between $5.89 and $5.99.
Further Company Coverage: Mrkn ((reuters.
Briefs@thomsonreuters.
Com;)).